SCHEMBL17099221

SCHEMBL17099221

O=C(CN(Cc1ccc(F)cc1)C(=O)c1cnn([C@H]2CC[C@H](C(=O)O)C2)c1C(F)(F)F)c1c(Cl)cncc1Cl

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
GAA P10253 2/20 0.33
PTPN1 P18031 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
TAS2R14 Q9NYV8 1/20 0.32
CCR5 P51681 3/20 0.32
MALT1 Q9UDY8 1/20 0.31
NR3C1 P04150 6/20 0.31
CYP1A2 P05177 3/20 0.31
CYP3A4 P08684 3/20 0.31
CYP2D6 P10635 3/20 0.31
CYP2C9 P11712 3/20 0.31
CYP2C19 P33261 3/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
DDR1 Q08345 1/20 0.30
MAPK11 Q15759 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17098714 1.00 ALDH1A1 (0.34) ALDH1A1MAPTGAAPTPN1KDM4E
SCHEMBL17097855 0.95 TAS2R14 (0.34) ALDH1A1MAPTGAAPTPN1KDM4E
SCHEMBL17098647 0.95 TAS2R14 (0.34) ALDH1A1MAPTGAAPTPN1KDM4E
SCHEMBL17048997 0.95 TAS2R14 (0.34) ALDH1A1MAPTGAAPTPN1KDM4E
SCHEMBL17099161 0.94 ALDH1A1 (0.34) ALDH1A1MAPTGAAPTPN1KDM4E
SCHEMBL17098897 0.94 ALDH1A1 (0.34) ALDH1A1MAPTGAAPTPN1KDM4E
SCHEMBL17098900 0.94 ALDH1A1 (0.34) ALDH1A1MAPTGAAPTPN1KDM4E
SCHEMBL17099157 0.91 TAS2R14 (0.33) ALDH1A1MAPTGAAPTPN1KDM4E
SCHEMBL17099160 0.91 TAS2R14 (0.33) ALDH1A1MAPTGAAPTPN1KDM4E
SCHEMBL17098595 0.90 CYP3A4 (0.34) ALDH1A1MAPTGAAPTPN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US claimed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US claimed
EP-3110810-B1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LTD (JP) 2018-05-02 EP disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266824-A1 Pyrazole Amide Derivative RORC, RORB, RORA ALDH1A1 923/4885MAPT 3584/4885GAA 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.